A Phase I Clinical Study for Evaluating the Safety of MASCT-I in Advanced Soild Tumor
Status:
Unknown status
Trial end date:
2020-07-01
Target enrollment:
Participant gender:
Summary
This study evaluate the safety and tolerance of MASCT-I(multiple-antigen specific cell
therapy) combined with PD1 antibody in patients with advanced gastric cancer who failed in
first-line chemotherapy. The study is divided into three stages: the first, second stage is
the stage of the dose climbing, and the third stage is the dose expansion stage. The patients
would be treated with MASCT-I single drug therapy, MASCT-I+ low dose PD1 antibody therapy,
and MASCT-I+ high dose PD1 antibody therapy.